Sorafenib and radiation: A promising combination in colorectal cancer

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 1, 2010, Pages 213-220

  Suen, Andrew W ^a   Galoforo, Sandra ^a   Marples, Brian ^a   McGonagle, Michele ^a   Downing, Laura ^a   Martinez, Alvaro A ^a   Robertson, John M ^a   Wilson, George D ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Growth delay; Radiation; Sorafenib; Targeted agents; Xenograft

Indexed keywords

ANGIOGENESIS; CELL SURVIVAL; CLONOGENIC ASSAYS; CLONOGENIC SURVIVAL ASSAYS; COLORECTAL CANCER; COLORECTAL CANCER CELL; COMBINED TREATMENT; GROWTH DELAY; GROWTH INHIBITION; IN-VITRO; IN-VIVO; MINIMAL EFFECTS; MTT ASSAYS; OPTIMAL TIMING; RADIATION RESPONSE; SORAFENIB; TARGETED AGENTS; THRESHOLD VOLUME; TUMOR SIZE; XENOGRAFT;

CELL CULTURE; CELLS; GROWTH KINETICS; OPTIMIZATION; RADIATION EFFECTS; TIME MEASUREMENT; TUMORS;

RADIOTHERAPY;

SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CLONOGENIC ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL DIVISION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN KINASE INHIBITORS; PYRIDINES; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RANDOM ALLOCATION; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 77955904732     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.02.064     Document Type: Article

References (35)

1. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
2. F. Egberts, K.C. Kahler, and E. Livingstone Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results Onkologie 31 2008 398 403
3. R.C. Kane, A.T. Farrell, and H. Saber Sorafenib for the treatment of advanced renal cell carcinoma Clin Cancer Res 12 2006 7271 7278
4. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
5. L. Liu, Y. Cao, and C. Chen Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858
6. W. Zhang, M. Konopleva, and Y.X. Shi Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia J Natl Cancer Inst 100 2008 184 198
7. H. Linardou, I.J. Dahabreh, and D. Kanaloupiti Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 2008 962 972
8. C.H. Takimoto, and A. Awada Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials Cancer Chemother Pharmacol 61 2008 535 548
9. L. Dal Lago, V. D'Hondt, and A. Awada Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors Oncologist 13 2008 845 858
10. D. Curran, J. Giralt, and P.M. Harari Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab J Clin Oncol 25 2007 2191 2197
11. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
12. P.M. Harari, G.W. Allen, and J.A. Bonner Biology of interactions: Antiepidermal growth factor receptor agents J Clin Oncol 25 2007 4057 4065
13. J.P. Plastaras, S.H. Kim, and Y.Y. Liu Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation Cancer Res 67 2007 9443 9454
14. J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
15. J.P. Gerard, T. Conroy, and F. Bonnetain Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203 J Clin Oncol 24 2006 4620 4625
16. R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
17. M.S. Roh, L.H. Colangelo, and M.J. O'Connell Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03 J Clin Oncol 27 2009 5124 5130
18. L. Ugidos, S. Delgado, and C. Conill Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients Invest New Drugs 27 2009 262 268
19. G.A. Hospers, C.J. Punt, and M.E. Tesselaar Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group Ann Surg Oncol 14 2007 2773 2779
20. F. Marquardt, F. Rodel, and G. Capalbo Molecular targeted treatment and radiation therapy for rectal cancer Strahlenther Onkol 185 2009 371 378
21. R. Kopp, E. Rothbauer, and E. Mueller Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels Dis Colon Rectum 46 2003 1391 1399
22. F. Bertolini, C. Bengala, and L. Losi Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy Int J Radiat Oncol Biol Phys 68 2007 1455 1461
23. S. Cascinu, F. Graziano, and V. Catalano An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation Br J Cancer 86 2002 744 749
24. B.G. Czito, J.C. Bendell, and C.G. Willett Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results Int J Radiat Oncol Biol Phys 68 2007 472 478
25. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
26. C.G. Willett, S.V. Kozin, and D.G. Duda Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice Semin Oncol 33 2006 S35 S40
27. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
28. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
29. V. Heinemann, S. Stintzing, and T. Kirchner Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR Cancer Treat Rev 35 2009 262 271
30. L. Barault, N. Veyrie, and V. Jooste Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers Int J Cancer 122 2008 2255 2259
31. T.E. Hutson, R.A. Figlin, and J.G. Kuhn Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies Oncologist 13 2008 1084 1096
32. S.M. Huang, and P.M. Harari Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clin Cancer Res 6 2000 2166 2174
33. S.S. Sridhar, D. Hedley, and L.L. Siu Raf kinase as a target for anticancer therapeutics Mol Cancer Ther 4 2005 677 685
34. J.A. McCubrey, L.S. Steelman, and S.L. Abrams Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Adv Enzyme Regul 46 2006 249 279
35. W.Y. Tang, S.P. Chau, and W.P. Tsang The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells Oncol Rep 12 2004 1349 1354